Jefferies Reiterates Buy Rating on Valneva (VALN) After Phase 3 Data

On March 23, 2026, Jefferies reiterated a Buy standing and $15 terms people connected Valneva SE (NASDAQ:VALN) pursuing topline results from the Phase 3 VALOR proceedings of its Lyme illness vaccine campaigner PF-07307405. Jefferies said that the banal absorption reflects a header miss connected statistical significance, noting 73.2% efficacy astatine 28 days post-dose did not conscionable the required threshold connected the little bound of the assurance interval. The steadfast has added that the weakness presents a buying accidental connected the shares of Valneva SE (NASDAQ:VALN) with a way to support inactive intact.

On the aforesaid day, Pfizer and Valneva SE (NASDAQ:VALN) person announced the topline results from the Phase 3 VALOR proceedings showing 73.2% efficacy from 28 days post-dose and 74.8% efficacy from 1 time post-dose successful reducing confirmed Lyme illness cases versus placebo. Pfizer and Valneva SE (NASDAQ:VALN) person said that less cases than expected were recorded, and the archetypal pre-specified statistical criterion was not met, but noted the 2nd investigation showed a assurance interval little bound supra 20, supporting plans for regulatory submissions.

Pixabay/Public Domain

Valneva SE (NASDAQ:VALN) develops, manufactures, and commercializes vaccines for infectious diseases.

While we admit the imaginable of VALN arsenic an investment, we judge definite AI stocks connection greater upside imaginable and transportation little downside risk. If you're looking for an highly undervalued AI banal that besides stands to payment importantly from Trump-era tariffs and the onshoring trend, spot our escaped study connected the best short-term AI stock.

READ NEXT: 33 Stocks That Should Double successful 3 Years and Cathie Wood 2026 Portfolio: 10 Best Stocks to Buy. 

Disclosure: None. Follow Insider Monkey connected Google News.